Vistagen Therapeutics (VTGN) EBT Margin (2017 - 2025)
Historic EBT Margin for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to 6237.29%.
- Vistagen Therapeutics' EBT Margin fell 2163500.0% to 6237.29% in Q4 2025 from the same period last year, while for Dec 2025 it was 8486.84%, marking a year-over-year decrease of 13746500.0%. This contributed to the annual value of 10578.4% for FY2025, which is 78191800.0% down from last year.
- According to the latest figures from Q4 2025, Vistagen Therapeutics' EBT Margin is 6237.29%, which was down 2163500.0% from 7525.97% recorded in Q3 2025.
- In the past 5 years, Vistagen Therapeutics' EBT Margin ranged from a high of 90900.0% in Q1 2025 and a low of 42789.74% during Q1 2022
- In the last 5 years, Vistagen Therapeutics' EBT Margin had a median value of 5613.88% in 2024 and averaged 2076.2%.
- In the last 5 years, Vistagen Therapeutics' EBT Margin plummeted by -413845400bps in 2022 and then soared by 967048800bps in 2025.
- Quarter analysis of 5 years shows Vistagen Therapeutics' EBT Margin stood at 2942.46% in 2021, then plummeted by -84bps to 5422.89% in 2022, then surged by 72bps to 1545.01% in 2023, then plummeted by -290bps to 6020.94% in 2024, then decreased by -4bps to 6237.29% in 2025.
- Its last three reported values are 6237.29% in Q4 2025, 7525.97% for Q3 2025, and 6186.48% during Q2 2025.